Organisation paid for research Program year 2025 Source: CMS Open Payments

Nci Clinical Repository

Neither a doctor nor a teaching hospital

Research payments

$266,240,082

105 payments

Through program year 2025, Nci Clinical Repository is reported as receiving $266,240,082 in research payments, across 105 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$39,699,286	28
2024	Research	$6,332,452	6
2023	Research	$20,028,558	12
2022	Research	$50,487,495	23
2021	Research	$55,761,374	4
2020	Research	$64,939,153	26
2019	Research	$28,991,764	6

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $194,290,061 12 payments
AbbVie, Inc. $37,947,124 41 payments
Pfizer Inc. $34,000,837 51 payments
Verastem, Inc. $2,060 1 payment

Studies the money was for Research payments · program years 2019–2025

103 CRADA various titles $176,021,427 8 payments
CRADA: Woyach_A041702_A Randomized Phase III Study of Ibruti $27,388,772 17 payments
Amg 678 Crada $9,793,227 3 payments
A Phase II Study of AMG 510 In Patients with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non $8,475,408 1 payment
A Randomized Phase 2 Trial of Axitinib Or Nivolumab Combination Therapy VS Single Agent Axitinib Or Nivolumab for the Treatment of Tfe Or Translocation Renal Cell Carcinoma Across All Age Groups $6,722,466 7 payments
CRADA Woyach_A041702_A Randomized Phase III Study of Ibrutinibnib $6,292,956 5 payments
A Biomarkerdriven Protocol for Previously Treated Nsclc Alk Positive Patients the Ncinrgalk Master Protocol $4,866,751 10 payments
Master Crada 13100023 Clinical Studies With Pfizer Incs Proprietary Anticancer Agents $4,673,709 7 payments
CRADA: Woyach_A041702_A Randomized Phase III Study of Ibrutinib $4,089,037 3 payments
A Phase II Openlabel Multicenter Clinical Trial of Inotuzumab Ozagamicin Followed By Blinatumomab for Older Adults With Untreated Cd22positive Phnegative Blineage All Or Adults With Relapsed Or Refractory Cd22positive Blineage All $3,967,766 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.